OncoFAP-Drug Conjugate

OncoFAP is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP).

 

The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas).

The OncoFAP product consists of a (i) small organic ligand targeting FAP, (ii) an innovative cleavable linker and (iii) a cytotoxic payload.

 OncoFAP displays best-in-class performance both in vitro  and in vivo with the highest reported affinity to the FAP antigen. In preclinical models of cancer, the product has shown a very rapid and selective accumulation in the tumor mass with an exceptionally low uptake uptake in healthy organs.

Thanks to the pan-tumoral potential of the ligand, OncoFAP-drug conjugate is being envisaged for therapeutic applications of various solid tumor.

ONGOING CLINICAL TRIALS
  • Two pivotal clinical trials with Fibromun in combination with doxorubicin in metastatic Soft Tissue Sarcoma are ongoing in Europe (EudraCT:2016-003239-38) and in the USA (NCT03420014).
  • A phase II clinical trial with Fibromun in combination with dacarbazine in pretreated Soft Tissue Sarcoma (EudraCT:2018-004104-19).
  • A phase I/II clinical trial with Fibromun (monotherapy) in grade III/IV glioma at first relapse (NCT03779230).
  • A phase I/II/IIb clinical trial with Fibromun in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma (NCT04443010).
  • A phase I/II clinical trial with Fibromun in combination with lomustine in grade III/IV glioma at first relapse (NCT04573192).
References